Cephalon Finalizes $425M Deal Over Off-Label Claims

Law360, New York (September 29, 2008, 12:00 AM EDT) -- Cephalon Inc. has finalized a $425 million settlement with the federal government to end allegations by company sales representatives and others that it marketed three of its drugs for uses that were not approved by the U.S. Food and Drug Administration.

In the deal announced Monday by the U.S. Department of Justice, Cephalon has agreed to plead guilty to one misdemeanor violation of the U.S. Food, Drug and Cosmetic Act. It also entered into a five-year corporate integrity agreement, which requires the drugmaker to send doctors...
To view the full article, register now.